Contrasting Opiant Pharmaceuticals (OPNT) & Rio Tinto (RIO)

Opiant Pharmaceuticals (NASDAQ:OPNT) and Rio Tinto (NYSE:RIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Risk and Volatility

Opiant Pharmaceuticals has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Rio Tinto has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.

Insider & Institutional Ownership

4.8% of Opiant Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Rio Tinto shares are owned by institutional investors. 37.9% of Opiant Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Opiant Pharmaceuticals and Rio Tinto, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 1 0 3.00
Rio Tinto 2 9 7 0 2.28

Opiant Pharmaceuticals currently has a consensus target price of $32.00, indicating a potential upside of 84.76%. Rio Tinto has a consensus target price of $55.67, indicating a potential upside of 7.87%. Given Opiant Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Opiant Pharmaceuticals is more favorable than Rio Tinto.


Rio Tinto pays an annual dividend of $2.54 per share and has a dividend yield of 4.9%. Opiant Pharmaceuticals does not pay a dividend. Rio Tinto pays out 53.0% of its earnings in the form of a dividend.

Valuation & Earnings

This table compares Opiant Pharmaceuticals and Rio Tinto’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $18.45 million 2.65 $6.58 million $2.94 5.89
Rio Tinto $40.03 billion 1.70 $8.76 billion $4.79 10.78

Rio Tinto has higher revenue and earnings than Opiant Pharmaceuticals. Opiant Pharmaceuticals is trading at a lower price-to-earnings ratio than Rio Tinto, indicating that it is currently the more affordable of the two stocks.


This table compares Opiant Pharmaceuticals and Rio Tinto’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals -449.52% -471.43% -190.80%
Rio Tinto N/A N/A N/A


Rio Tinto beats Opiant Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.

Rio Tinto Company Profile

Rio Tinto plc, a mining and metals company, explores for, develops, produces, and processes minerals and metals worldwide. It finds, mines, and processes mineral resources, including aluminum, copper, diamonds, gold, industrial minerals (borates, titanium dioxide, and salt), iron ore, thermal and metallurgical coal, and uranium, as well as sulphuric acid, rhenium, lead carbonate, and selenium. The company was founded in 1873 and is headquartered in London, the United Kingdom. Rio Tinto plc operates as a subsidiary of Rio Tinto Group.

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply